← 產業報告目錄

Neuromodulation Market by Technology (Internal, External), Stimulation Type (Spinal Cord, Deep Brain, Vagus Nerve Stimulation), Application (Ischemia, Depression, Epilepsy, Obesity), End User (Hospitals, ASCs, Clinics) & Region - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2025-09-15頁數 367報告編號 BT3571

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global neuromodulation market is projected to reach USD 10.68 billion by 2030 from USD 6.81 billion in 2025, at a CAGR of 9.4% during the forecast period. The neuromodulation market is expanding due to the rising prevalence of neurological disorders, the development of new neuromodulation technologies, and the increasing geriatric population, all of which contribute to market growth. Additionally, the high cost of neuromodulation procedures may limit the market growth. “The hospitals & ambulatory surgery centers segment of the neuromodulation end user market is expected to hold the largest position during the forecast period.” By end user, it is segmented into hospitals & ambulatory surgery centers, clinics & physiotherapy centers, and other end users. In 2024, hospitals & ambulatory surgery centers will hold the largest market share. The hospitals and ambulatory care segment dominates the neuromodulation market due to its ability to provide comprehensive, multidisciplinary care and access to advanced neuromodulation therapies. These settings are equipped with specialized surgical facilities, trained clinicians, and monitoring systems necessary for implantable and complex neuromodulation procedures. Hospitals and ambulatory centers also benefit from established reimbursement frameworks, making costly procedures more accessible to patients. Moreover, the increasing focus on chronic disease management, postoperative care, and patient follow-up is driving high procedure volumes in these settings, reinforcing their leadership in neuromodulation delivery solutions. “The internal neuromodulation accounted for the largest market share in the neuromodulation market.” The neuromodulation technology market is segmented into internal neuromodulation and external neuromodulation. The internal neuromodulation segment accounted for the largest share in the neuromodulation market in 2024. Internal neuromodulation has become the dominant approach in the market due to its sophisticated technology that facilitates targeted stimulation of specific neural pathways. This process is instrumental in the chronic management of conditions such as nociceptive pain, Parkinson's disease, and urinary or fecal incontinence. The implantable devices are characterized by features like rechargeable or long-lasting batteries, customizable stimulation protocols, closed-loop feedback mechanisms, and wireless connectivity. These capabilities enable real-time monitoring and tailored therapeutic adjustments to enhance patient outcomes. The technological advancements support compact device designs that minimize invasiveness, thereby improving patient comfort and adherence to treatment. Furthermore, ongoing innovation in materials science, electrode architecture, and software algorithms continues to improve the efficacy, safety, and longevity of these systems. As a result, internal neuromodulation is increasingly favored over non-invasive interventions in clinical practice. “The Asia Pacific is the fastest-growing region of the neuromodulation market by region.” The global neuromodulation market is divided into five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is the fastest-growing area in the neuromodulation market due to increasing health awareness, a rising rate of neurological and chronic pain disorders, and expanding healthcare infrastructure in countries like China, India, and Japan. The region is seeing greater adoption of advanced neuromodulation technologies, helped by better reimbursement policies and government efforts to improve access to medical devices. Additionally, a large patient population, higher disposable incomes, and increased investments from both global and local device manufacturers are fueling market growth. The push to establish specialized treatment centers and the gradual adoption of minimally invasive and implantable products further boost neuromodulation use in the region. Moreover, the rise in medical tourism in countries such as India, Thailand, and Singapore is increasing surgical volumes, which in turn raises the demand for post-operative care and neuromodulation. A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1: 28%, Tier 2: 42%, and Tier 3: 30% • By Designation: C Level: 30%, Director Level: 34%, and Others: 36% • By Region: North America: 51%, Europe: 21%, Asia Pacific: 18%, Latin America: 6%, and Middle East & Africa: 4% Note 1: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion. Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs. Note 3: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers. The major players operating in the neuromodulation market are Medtronic (US), Boston Scientific Corporation (US), Abbott (US), LivaNova PLC (UK), Nevro Corp (US), NeuroPace, Inc. (US), Bioventus (US), electroCore, Inc. (US), Helius Medical Technologies, Inc. (US), and Neuronetics (US). Research Coverage This report examines the neuromodulation market based on technology, stimulation type, application, end user, and country. It also analyzes factors such as drivers, restraints, opportunities, and challenges that influence market growth, along with details of the competitive landscape for market leaders. Additionally, the report studies micro markets according to their individual growth trends. It forecasts the revenue of market segments across five major regions and their respective countries. Reasons to Buy the Report The report will help both established and smaller firms to understand market trends, which, in turn, will assist them in gaining a larger market share. Companies purchasing the report can use one or a combination of the strategies listed below to strengthen their market position. This report provides insights into the following pointers:  Analysis of key drivers (rising prevalence of neurological disorders and nerve injuries, rising geriatric population and subsequent growth in prevalence of neurological disorders, rising government support and funding for neurological disorders, increasing focus on development of advanced neuromodulation and neurostimulation technologies, increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices, and availability of reimbursements for neuromodulation devices), restraints (high cost of neuromodulation procedures, preference for drug therapies over neuromodulation products, and adverse effects and complications associated with neuromodulation devices), opportunities (large population and increasing healthcare expenditure in emerging economies, and widening application scope of neuromodulation), challenges (stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices, and shortage of trained professionals)  Market Penetration: Comprehensive information on the product portfolios offered by the top players in the neuromodulation market  Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the neuromodulation market  Market Development: Comprehensive information on lucrative emerging regions  Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the neuromodulation market  Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players
目錄 Table of Contents
1 INTRODUCTION 37 1.1 STUDY OBJECTIVES 37 1.2 MARKET DEFINITION 37 1.3 STUDY SCOPE 38 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 38 1.3.2 INCLUSIONS & EXCLUSIONS 39 1.3.3 YEARS CONSIDERED 40 1.3.4 CURRENCY CONSIDERED 41 1.4 STAKEHOLDERS 41 1.5 SUMMARY OF CHANGES 41 2 RESEARCH METHODOLOGY 43 2.1 RESEARCH DATA 43 2.1.1 SECONDARY DATA 44 2.1.1.1 List of key secondary sources 44 2.1.1.2 Key data from secondary sources 44 2.1.2 PRIMARY DATA 45 2.1.2.1 Key objectives of primary research 45 2.1.2.2 List of primary sources 45 2.1.2.3 Key data from primary sources 46 2.1.2.4 Breakdown of primary interviews 47 2.1.2.5 Insights from industry experts 48 2.2 MARKET SIZE ESTIMATION 48 2.2.1 BOTTOM-UP APPROACH 48 2.2.1.1 Revenue estimation of key players 49 2.2.1.2 Study of annual reports and investor presentations 49 2.2.1.3 Primary interviews 49 2.2.1.4 Growth forecast 49 2.2.1.5 CAGR projections 50 2.2.2 TOP-DOWN APPROACH 50 2.3 DATA TRIANGULATION 51 2.4 STUDY ASSUMPTIONS 52 2.4.1 RESEARCH-RELATED ASSUMPTIONS 52 2.4.2 PARAMETRIC ASSUMPTIONS 52 2.4.3 GROWTH-RATE ASSUMPTIONS 52 2.4.4 MARKET ASSUMPTIONS 53 2.5 RESEARCH LIMITATIONS 53 2.6 RISK ANALYSIS 54 3 EXECUTIVE SUMMARY 55 4 PREMIUM INSIGHTS 59 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN NEUROMODULATION MARKET 59 4.2 ASIA PACIFIC: NEUROMODULATION MARKET, BY END USER AND COUNTRY, 2024 60 4.3 NEUROMODULATION MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 61 4.4 NEUROMODULATION MARKET: REGIONAL MIX 62 5 MARKET OVERVIEW 63 5.1 INTRODUCTION 63 5.2 MARKET DYNAMICS 63 5.2.1 DRIVERS 64 5.2.1.1 Rising prevalence of neurological disorders and nerve injuries 64 5.2.1.2 High incidence of neurological disorders among geriatric population 64 5.2.1.3 Favorable government support and funding with advanced healthcare infrastructure 65 5.2.1.4 Development of advanced neuromodulation and neurostimulation technologies 65 5.2.1.5 Growing collaborations among device manufacturers, healthcare providers, and research institutions 66 5.2.1.6 Availability of reimbursements for neuromodulation devices 66 5.2.2 RESTRAINTS 66 5.2.2.1 High cost of neuromodulation procedures 66 5.2.2.2 Preference for drug therapies over neuromodulation products 67 5.2.2.3 Adverse effects and complications with neuromodulation devices 67 5.2.3 OPPORTUNITIES 67 5.2.3.1 Large population and high healthcare expenditure in emerging economies 67 5.2.3.2 Widening application scope of neuromodulation 68 5.2.4 CHALLENGES 68 5.2.4.1 Stringent regulatory framework and time-consuming approval processes for neuromodulation and neurostimulation devices 68 5.2.4.2 Shortage of trained professionals 69 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 69 5.4 PRICING ANALYSIS 70 5.4.1 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY STIMULATION TYPE, 2023–2025 70 5.4.2 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY KEY PLAYER, 2023–2025 70 5.4.3 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY REGION, 2023–2025 71 5.5 VALUE CHAIN ANALYSIS 72 5.6 SUPPLY CHAIN ANALYSIS 73 5.7 ECOSYSTEM ANALYSIS 74 5.8 INVESTMENT & FUNDING SCENARIO 75 5.9 TECHNOLOGY ANALYSIS 76 5.9.1 KEY TECHNOLOGIES 76 5.9.1.1 Transcutaneous electrical nerve stimulation 76 5.9.2 COMPLEMENTARY TECHNOLOGIES 77 5.9.2.1 Wearable biosensors 77 5.9.3 ADJACENT TECHNOLOGIES 77 5.9.3.1 Regenerative medicine and stem cells 77 5.10 PATENT ANALYSIS 77 5.10.1 LIST OF KEY PATENTS 79 5.11 TRADE DATA ANALYSIS 80 5.11.1 IMPORT DATA FOR HS CODE 901890 80 5.11.2 EXPORT DATA FOR HS CODE 901890 80 5.12 KEY CONFERENCES & EVENTS, 2025–2026 81 5.13 CASE STUDY ANALYSIS 82 5.13.1 USE OF NEURALMODULATION TECHNOLOGIES IN RESEARCH, CLINICAL PRACTICE, AND CONSUMER APPLICATIONS 82 5.13.2 PAIRING TRANSLINGUAL NEUROSTIMULATION WITH INTENSIVE REHABILITATION TO ENHANCE NEUROPLASTICITY AND IMPROVE MOTOR RECOVERY IN SEVERE TRAUMATIC BRAIN INJURY PATIENTS 82 5.13.3 APPLICATION OF NEUROMODULATION TECHNIQUES—FROM NON-INVASIVE BRAIN STIMULATION TO DEEP BRAIN STIMULATION 83 5.14 REGULATORY ANALYSIS 84 5.14.1 REGULATORY LANDSCAPE 84 5.14.1.1 North America 84 5.14.1.1.1 US 84 5.14.1.1.2 Canada 84 5.14.1.2 Europe 84 5.14.1.3 Asia Pacific 85 5.14.1.3.1 China 85 5.14.1.3.2 Japan 85 5.14.1.3.3 India 86 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 5.15 PORTER’S FIVE FORCES ANALYSIS 89 5.15.1 BARGAINING POWER OF SUPPLIERS 90 5.15.2 BARGAINING POWER OF BUYERS 90 5.15.3 THREAT OF NEW ENTRANTS 90 5.15.4 THREAT OF SUBSTITUTES 90 5.15.5 INTENSITY OF COMPETITIVE RIVALRY 91 5.16 KEY STAKEHOLDERS & BUYING CRITERIA 91 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS 91 5.16.2 KEY BUYING CRITERIA 92 5.17 IMPACT OF AI/GEN AI ON NEUROMODULATION MARKET 92 5.17.1 INTRODUCTION 92 5.17.2 POTENTIAL OF AI 93 5.17.3 IMPACT OF AI 93 5.17.4 KEY COMPANIES IMPLEMENTING AI 94 5.17.5 FUTURE OF AI 94 5.18 IMPACT OF 2025 US TARIFF ON NEUROMODULATION MARKET 94 5.18.1 INTRODUCTION 94 5.18.2 KEY TARIFF RATES 95 5.18.3 PRICE IMPACT ANALYSIS 96 5.18.4 IMPACT ON COUNTRY/REGION 96 5.18.4.1 North America 96 5.18.4.2 Europe 96 5.18.4.3 Asia Pacific 97 5.18.5 IMPACT ON END-USE INDUSTRIES 97 5.18.5.1 Hospitals 97 6 NEUROMODULATION MARKET, BY TECHNOLOGY 98 6.1 INTRODUCTION 99 6.2 INTERNAL NEUROMODULATION 99 6.2.1 INTERNAL NEUROMODULATION TO RESULT IN BETTER TREATMENT RESULTS AND LOWER HEALTHCARE COSTS 99 6.3 EXTERNAL NEUROMODULATION 101 6.3.1 RISING DEMAND FOR NON-INVASIVE SOLUTIONS FOR NEUROLOGICAL AND PAIN-RELATED DISORDERS TO FUEL GROWTH 101 7 NEUROMODULATION MARKET, BY STIMULATION TYPE 105 7.1 INTRODUCTION 106 7.2 SPINAL CORD STIMULATION 107 7.2.1 GROWING INCIDENCE OF SPINAL CORD INJURIES TO FUEL MARKET GROWTH 107 7.3 DEEP BRAIN STIMULATION 110 7.3.1 MINIMALLY INVASIVE DEEP BRAIN STIMULATION TO DELIVER CONTROLLED ELECTRICAL IMPULSES AND REDUCE SIDE EFFECTS 110 7.4 SACRAL NERVE STIMULATION 113 7.4.1 INCREASING PREVALENCE OF CHRONIC URINARY INCONTINENCE AMONG ELDERLY WOMEN TO PROPEL MARKET GROWTH 113 7.5 VAGUS NERVE STIMULATION 116 7.5.1 RISING INCIDENCE OF EPILEPSY TO DRIVE ADOPTION OF NEXT-GENERATION VAGUS NERVE STIMULATION THERAPY 116 7.6 GASTRIC NERVE STIMULATION 119 7.6.1 INCREASING PREVALENCE OF GASTROESOPHAGEAL REFLUX DISEASE AND GASTROPARESIS TO FUEL MARKET GROWTH 119 7.7 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION 122 7.7.1 LOW COST AND EASE OF USE TO FUEL ADOPTION IN HEALTHCARE SECTOR 122 7.8 TRANSCRANIAL MAGNETIC STIMULATION 125 7.8.1 MINIMAL PATIENT DISCOMFORT ASSOCIATED WITH TRANSCRANIAL MAGNETIC STIMULATION TO SUPPORT DEMAND 125 7.9 RESPIRATORY ELECTRICAL STIMULATION 128 7.9.1 HIGH TREATMENT EFFICACY AND INCREASED FOCUS ON MINIMALLY INVASIVE SPINAL CORD TREATMENT TO FUEL MARKET GROWTH 128 7.10 OTHER STIMULATION TYPES 131 8 NEUROMODULATION MARKET, BY APPLICATION 135 8.1 INTRODUCTION 136 8.2 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION 136 8.2.1 CHRONIC PAIN 136 8.2.1.1 High incidence of chronic pain among geriatric population to support market growth 136 8.2.2 FAILED BACK SURGERY SYNDROME 139 8.2.2.1 Increasing number of spinal surgeries to aid market growth 139 8.2.3 ISCHEMIA 142 8.2.3.1 High effectiveness of neuromodulation to boost effectiveness for ischemia treatment 142 8.3 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION 144 8.3.1 PARKINSON’S DISEASE 144 8.3.1.1 Development of advanced solutions and increased R&D to improve market growth 144 8.3.2 TREMORS 147 8.3.2.1 Increased prevalence of tremors and high efficacy of deep brain stimulation to drive market 147 8.3.3 DEPRESSION 149 8.3.3.1 Ongoing research and clinical studies to boost adoption of deep brain stimulation for depression treatment 149 8.3.4 OTHER DEEP BRAIN STIMULATION APPLICATIONS 152 8.4 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION 155 8.4.1 URINE INCONTINENCE 155 8.4.1.1 High incidence of urine incontinence to offer growth opportunities for market players 155 8.4.2 FECAL INCONTINENCE 158 8.4.2.1 Reduced symptom recurrence with sacral nerve stimulation to aid long-term management of fecal incontinence 158 8.5 NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION 161 8.5.1 EPILEPSY 161 8.5.1.1 Low risk with device implantation and long-lasting battery life to aid market growth 161 8.5.2 OTHER VAGUS NERVE STIMULATION APPLICATIONS 163   8.6 NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION 166 8.6.1 GASTROPARESIS 166 8.6.1.1 Reduced hospitalization time associated with sastroparesis treatment to augment market growth 166 8.6.2 OBESITY 169 8.6.2.1 High prevalence of obesity and risks associated with gastric bypass to propel market growth 169 8.7 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION 172 8.7.1 TREATMENT-RESISTANT DEPRESSION 172 8.7.1.1 High prevalence of chronic and recurrent depression to augment market growth 172 8.7.2 OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS 175 8.8 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION 178 8.8.1 DEPRESSION 179 8.8.1.1 Repeated transcranial magnetic stimulation to be well-tolerated procedure with improved acceptance among patients 179 8.8.2 MIGRAINE 181 8.8.2.1 High prevalence of migraines to support market growth 181 8.9 NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY APPLICATION 184 8.9.1 INCREASING INCIDENCE OF SPINAL CORD INJURIES TO ENSURE CONTINUED DEMAND FOR ADVANCED TREATMENT OPTIONS 184 8.10 OTHER APPLICATIONS 186 9 NEUROMODULATION MARKET, BY END USER 189 9.1 INTRODUCTION 190 9.2 HOSPITALS & AMBULATORY SURGERY CENTERS 190 9.2.1 ADVANCED INFRASTRUCTURE AND ABILITY TO MANAGE COMPLEX NEUROLOGICAL CASES TO PROPEL MARKET GROWTH 190 9.3 CLINICS & PHYSIOTHERAPY CENTERS 193 9.3.1 NEED FOR FOCUSED EXPERTISE AND BETTER REHABILITATION MANAGEMENT TO ACCELERATE MARKET EXPANSION 193 9.4 OTHER END USERS 196 10 NEUROMODULATION MARKET, BY REGION 199 10.1 INTRODUCTION 200 10.2 NORTH AMERICA 200 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 200 10.2.2 US 206 10.2.2.1 US to dominate North American neuromodulation market during forecast period 206   10.2.3 CANADA 210 10.2.3.1 Increasing neurological disorder rates and rising government funding to propel market growth 210 10.3 EUROPE 214 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 215 10.3.2 GERMANY 220 10.3.2.1 Advanced surgical innovations and favorable reimbursement policies to drive market 220 10.3.3 FRANCE 224 10.3.3.1 Favorable healthcare reforms to drive adoption of advanced neuromodulation techniques 224 10.3.4 UK 228 10.3.4.1 Increased public & private sector healthcare expenditure and investments to fuel market growth 228 10.3.5 ITALY 232 10.3.5.1 Rising cases of dementia and Alzheimer’s among geriatric population to spur market growth 232 10.3.6 SPAIN 236 10.3.6.1 Favorable government-led healthcare initiatives to support market growth 236 10.3.7 RUSSIA 240 10.3.7.1 Shifting demographic landscape and escalating neurological health needs to drive demand 240 10.3.8 REST OF EUROPE 244 10.4 ASIA PACIFIC 248 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 248 10.4.2 CHINA 254 10.4.2.1 Government-led healthcare reforms and high prevalence of neurological disorders to fuel demand 254 10.4.3 JAPAN 258 10.4.3.1 Innovative healthcare delivery and advanced infrastructure landscape to augment market growth 258 10.4.4 INDIA 262 10.4.4.1 Booming medical tourism and rising middle class with higher disposable incomes to accelerate market growth 262 10.4.5 AUSTRALIA 266 10.4.5.1 Increasing cases of depressive and post-traumatic stress disorders to propel market demand 266 10.4.6 REST OF ASIA PACIFIC 270 10.5 LATIN AMERICA 274 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 275 10.5.2 BRAZIL 279 10.5.2.1 Improvements in healthcare infrastructure to aid market growth 279 10.5.3 MEXICO 283 10.5.3.1 Expanding healthcare awareness and growing burden of neurological disorders to favor market growth 283 10.5.4 REST OF LATIN AMERICA 287 10.6 MIDDLE EAST & AFRICA 291 10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE AND INCREASED AWARENESS OF NEUROLOGICAL CARE TO DRIVE MARKET 291 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 292 11 COMPETITIVE LANDSCAPE 297 11.1 INTRODUCTION 297 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 297 11.2.1 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NEUROMODULATION MARKET 297 11.3 REVENUE ANALYSIS, 2020–2024 298 11.4 MARKET SHARE ANALYSIS, 2024 299 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 301 11.5.1 STARS 301 11.5.2 EMERGING LEADERS 301 11.5.3 PERVASIVE PLAYERS 302 11.5.4 PARTICIPANTS 302 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 303 11.5.5.1 Company footprint 303 11.5.5.2 Region footprint 303 11.5.5.3 Technology footprint 304 11.5.5.4 Stimulation type footprint 304 11.5.5.5 End-user footprint 305 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 305 11.6.1 PROGRESSIVE COMPANIES 305 11.6.2 RESPONSIVE COMPANIES 305 11.6.3 DYNAMIC COMPANIES 305 11.6.4 STARTING BLOCKS 306 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 307 11.6.5.1 Detailed list of key startups/SMEs 307 11.6.5.2 Competitive benchmarking of startups/SMEs 308 11.7 COMPANY VALUATION & FINANCIAL METRICS 310 11.7.1 COMPANY VALUATION 310 11.7.2 FINANCIAL METRICS 310 11.8 BRAND/PRODUCT COMPARISON 311 11.9 COMPETITIVE SCENARIO 312 11.9.1 PRODUCT LAUNCHES & APPROVALS 312 11.9.2 DEALS 313   12 COMPANY PROFILES 314 12.1 KEY PLAYERS 314 12.1.1 MEDTRONIC 314 12.1.1.1 Business overview 314 12.1.1.2 Products offered 316 12.1.1.3 Recent developments 316 12.1.1.3.1 Product approvals 316 12.1.1.4 MnM view 317 12.1.1.4.1 Right to win 317 12.1.1.4.2 Strategic choices 317 12.1.1.4.3 Weaknesses & competitive threats 317 12.1.2 BOSTON SCIENTIFIC CORPORATION 318 12.1.2.1 Business overview 318 12.1.2.2 Products offered 320 12.1.2.3 Recent developments 320 12.1.2.3.1 Product approvals 320 12.1.2.3.2 Deals 321 12.1.2.4 MnM view 321 12.1.2.4.1 Right to win 321 12.1.2.4.2 Strategic choices 321 12.1.2.4.3 Weaknesses & competitive threats 321 12.1.3 ABBOTT 322 12.1.3.1 Business overview 322 12.1.3.2 Products offered 323 12.1.3.3 Recent developments 324 12.1.3.3.1 Product launches and approvals 324 12.1.3.4 MnM view 324 12.1.3.4.1 Right to win 324 12.1.3.4.2 Strategic choices 324 12.1.3.4.3 Weaknesses & competitive threats 324 12.1.4 LIVANOVA PLC 325 12.1.4.1 Business overview 325 12.1.4.2 Products offered 326 12.1.4.3 Recent developments 327 12.1.4.3.1 Product launches 327 12.1.4.4 MnM view 327 12.1.4.4.1 Right to win 327 12.1.4.4.2 Strategic choices 327 12.1.4.4.3 Weaknesses & competitive threats 327 12.1.5 NEVRO CORP. 328 12.1.5.1 Business overview 328 12.1.5.2 Products offered 329 12.1.5.3 Recent developments 329 12.1.5.3.1 Product approvals 329 12.1.5.3.2 Deals 330 12.1.5.4 MnM view 330 12.1.5.4.1 Right to win 330 12.1.5.4.2 Strategic choices 330 12.1.5.4.3 Weaknesses & competitive threats 330 12.1.6 NEUROPACE, INC. 331 12.1.6.1 Business overview 331 12.1.6.2 Products offered 332 12.1.7 BIOVENTUS 333 12.1.7.1 Business overview 333 12.1.7.2 Products offered 334 12.1.7.3 Recent developments 335 12.1.7.3.1 Product approvals 335 12.1.8 ELECTROCORE, INC. 336 12.1.8.1 Business overview 336 12.1.8.2 Products offered 337 12.1.8.3 Recent developments 338 12.1.8.3.1 Product launches 338 12.1.8.3.2 Deals 338 12.1.9 HELIUS MEDICAL TECHNOLOGIES, INC. 339 12.1.9.1 Business overview 339 12.1.9.2 Products offered 340 12.1.9.3 Recent developments 341 12.1.9.3.1 Deals 341 12.1.10 NEURONETICS 342 12.1.10.1 Business overview 342 12.1.10.2 Products offered 343 12.1.10.3 Recent developments 344 12.1.10.3.1 Product approvals 344 12.1.10.3.2 Deals 344 12.2 OTHER PLAYERS 345 12.2.1 NEUROSIGMA, INC. 345 12.2.2 SOTERIX MEDICAL INC. 346 12.2.3 SYNAPSE BIOMEDICAL INC. 347 12.2.4 ALEVA NEUROTHERAPEUTICS 348 12.2.5 THERANICA BIO-ELECTRONICS LTD. 349 12.2.6 GIMER MEDICAL 350 12.2.7 NALU MEDICAL, INC. 351 12.2.8 MICROTRANSPONDER INC. 351 12.2.9 MAGSTIM 352 12.2.10 AMBER THERAPEUTICS 353 12.2.11 TVNS TECHNOLOGIES GMBH 354 12.2.12 BIOWAVE 355 12.2.13 BIOTRONIK 356 12.2.14 SALUDA MEDICAL PTY LTD. 357 12.2.15 SPR 358 13 APPENDIX 359 13.1 DISCUSSION GUIDE 359 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 363 13.3 CUSTOMIZATION OPTIONS 365 13.4 RELATED REPORTS 365 13.5 AUTHOR DETAILS 366
圖表清單 List of Tables & Figures
TABLE 1 NEUROMODULATION MARKET: INCLUSIONS & EXCLUSIONS 39 TABLE 2 NEUROMODULATION MARKET: KEY DATA FROM PRIMARY SOURCES 46 TABLE 3 MARKET ASSUMPTIONS IN NEUROMODULATION MARKET 53 TABLE 4 RISK ANALYSIS IN NEUROMODULATION MARKET 54 TABLE 5 POTENTIAL ADVERSE EFFECTS ASSOCIATED WITH DIFFERENT NEUROMODULATION DEVICES 67 TABLE 6 AVERAGE SELLING PRICING TREND OF NEUROMODULATION PRODUCTS, BY STIMULATION TYPE, 2023–2025 (USD) 70 TABLE 7 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY KEY PLAYER, 2023–2025 (USD) 71 TABLE 8 AVERAGE SELLING PRICE TREND OF NEUROMODULATION PRODUCTS, BY REGION, 2023–2025 (USD) 71 TABLE 9 ROLE OF KEY PLAYERS IN ECOSYSTEM (SUPPLY AND DEMAND SIDES) 75 TABLE 10 LIST OF KEY PATENTS IN NEUROMODULATION MARKET, 2022–2025 79 TABLE 11 IMPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020–2024 (USD MILLION) 80 TABLE 12 EXPORT DATA FOR HS CODE 901890, BY COUNTRY, 2020–2024 (USD MILLION) 80 TABLE 13 LIST OF KEY CONFERENCES & EVENTS IN NEUROMODULATION MARKET, JANUARY 2025–DECEMBER 2026 81 TABLE 14 CLASSIFICATION OF MEDICAL DEVICES BY US FDA 84 TABLE 15 NATIONAL MEDICAL PRODUCT ADMINISTRATION (NMPA) MEDICAL DEVICES CLASSIFICATION 85 TABLE 16 JAPAN: CLASSIFICATION OF MEDICAL DEVICES 86 TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87 TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 TABLE 20 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 88 TABLE 21 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 89 TABLE 22 IMPACT OF PORTER’S FIVE FORCES ON NEUROMODULATION MARKET 90 TABLE 23 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER (%) 91 TABLE 24 KEY BUYING CRITERIA, BY END USER 92 TABLE 25 KEY COMPANIES IMPLEMENTING AI IN NEUROMODULATION MARKET 94 TABLE 26 US-ADJUSTED RECIPROCAL TARIFF RATES 95 TABLE 27 NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 99 TABLE 28 INTERNAL NEUROMODULATION MARKET, BY REGION, 2023–2030 (USD MILLION) 100 TABLE 29 NORTH AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 30 EUROPE: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 100 TABLE 31 ASIA PACIFIC: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 32 LATIN AMERICA: INTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 101 TABLE 33 EXTERNAL NEUROMODULATION MARKET, BY REGION, 2023–2030 (USD MILLION) 102 TABLE 34 NORTH AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 102 TABLE 35 EUROPE: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 36 ASIA PACIFIC: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 103 TABLE 37 LATIN AMERICA: EXTERNAL NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 104 TABLE 38 NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 106 TABLE 39 SPINAL CORD STIMULATION DEVICES OFFERED BY KEY PLAYERS 107 TABLE 40 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY REGION, 2023–2030 (USD MILLION) 108 TABLE 41 NORTH AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 108 TABLE 42 EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 43 ASIA PACIFIC: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 109 TABLE 44 LATIN AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 110 TABLE 45 DEEP BRAIN STIMULATION DEVICES OFFERED BY KEY PLAYERS 111 TABLE 46 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY REGION, 2023–2030 (USD MILLION) 111 TABLE 47 NORTH AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 48 EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 112 TABLE 49 ASIA PACIFIC: NEUROMODULATION FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 50 LATIN AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 113 TABLE 51 SACRAL NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS 114 TABLE 52 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 53 NORTH AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 114 TABLE 54 EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 55 ASIA PACIFIC: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 115 TABLE 56 LATIN AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 116 TABLE 57 VAGUS NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS 116 TABLE 58 NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY REGION, 2023–2030 (USD MILLION) 117 TABLE 59 NORTH AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 117 TABLE 60 EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 61 ASIA PACIFIC: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 118 TABLE 62 LATIN AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 119 TABLE 63 GASTRIC NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS 119 TABLE 64 NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY REGION, 2023–2030 (USD MILLION) 120 TABLE 65 NORTH AMERICA: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 120 TABLE 66 EUROPE: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 67 ASIA PACIFIC: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 121 TABLE 68 LATIN AMERICA: NEUROMODULATION MARKET FOR GASTRIC NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 122 TABLE 69 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION DEVICES OFFERED BY KEY PLAYERS 123 TABLE 70 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY REGION, 2023–2030 (USD MILLION) 123 TABLE 71 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 123 TABLE 72 EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 73 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 124 TABLE 74 LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 125 TABLE 75 TRANSCRANIAL MAGNETIC STIMULATION DEVICES OFFERED BY KEY PLAYERS 125 TABLE 76 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 77 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 126 TABLE 78 EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 79 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 127 TABLE 80 LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 128 TABLE 81 RESPIRATORY ELECTRICAL STIMULATION DEVICES OFFERED BY KEY PLAYERS 128 TABLE 82 NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY REGION, 2023–2030 (USD MILLION) 129 TABLE 83 NORTH AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 129 TABLE 84 EUROPE: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 85 ASIA PACIFIC: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 130 TABLE 86 LATIN AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 131 TABLE 87 OTHER STIMULATION DEVICES OFFERED BY KEY PLAYERS 132 TABLE 88 NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY REGION, 2023–2030 (USD MILLION) 132 TABLE 89 NORTH AMERICA: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 132 TABLE 90 EUROPE: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 91 ASIA PACIFIC: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 133 TABLE 92 LATIN AMERICA: NEUROMODULATION MARKET FOR OTHER STIMULATION TYPES, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 93 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 136 TABLE 94 SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY REGION, 2023–2030 (USD MILLION) 137 TABLE 95 NORTH AMERICA: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023–2030 (USD MILLION) 137 TABLE 96 EUROPE: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 97 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023–2030 (USD MILLION) 138 TABLE 98 LATIN AMERICA: SPINAL CORD STIMULATION MARKET FOR CHRONIC PAIN, BY COUNTRY, 2023–2030 (USD MILLION) 139 TABLE 99 SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY REGION, 2023–2030 (USD MILLION) 139 TABLE 100 NORTH AMERICA: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 101 EUROPE: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023–2030 (USD MILLION) 140 TABLE 102 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 103 LATIN AMERICA: SPINAL CORD STIMULATION MARKET FOR FAILED BACK SURGERY SYNDROME, BY COUNTRY, 2023–2030 (USD MILLION) 141 TABLE 104 SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY REGION, 2023–2030 (USD MILLION) 142 TABLE 105 NORTH AMERICA: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023–2030 (USD MILLION) 142 TABLE 106 EUROPE: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 107 ASIA PACIFIC: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 108 LATIN AMERICA: SPINAL CORD STIMULATION MARKET FOR ISCHEMIA, BY COUNTRY, 2023–2030 (USD MILLION) 144 TABLE 109 NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 144 TABLE 110 DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY REGION, 2023–2030 (USD MILLION) 145 TABLE 111 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2023–2030 (USD MILLION) 145 TABLE 112 EUROPE: DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 113 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2023–2030 (USD MILLION) 146 TABLE 114 LATIN AMERICA: DEEP BRAIN STIMULATION MARKET FOR PARKINSON’S DISEASE, BY COUNTRY, 2023–2030 (USD MILLION) 147 TABLE 115 DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY REGION, 2023–2030 (USD MILLION) 147 TABLE 116 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 117 EUROPE: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023–2030 (USD MILLION) 148 TABLE 118 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 119 LATIN AMERICA: DEEP BRAIN STIMULATION MARKET FOR TREMORS, BY COUNTRY, 2023–2030 (USD MILLION) 149 TABLE 120 DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY REGION, 2023–2030 (USD MILLION) 150 TABLE 121 NORTH AMERICA: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION) 150 TABLE 122 EUROPE: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 123 ASIA PACIFIC: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION) 151 TABLE 124 LATIN AMERICA: DEEP BRAIN STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION) 152 TABLE 125 OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 153 TABLE 126 NORTH AMERICA: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 153 TABLE 127 EUROPE: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 128 ASIA PACIFIC: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 154 TABLE 129 LATIN AMERICA: OTHER DEEP BRAIN STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 130 NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, BY COUNTRY, 2023–2030 (USD MILLION) 155 TABLE 131 SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY REGION, 2023–2030 (USD MILLION) 156 TABLE 132 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION) 156 TABLE 133 EUROPE: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 134 ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION) 157 TABLE 135 LATIN AMERICA: SACRAL NERVE STIMULATION MARKET FOR URINE INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION) 158 TABLE 136 SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY REGION, 2023–2030 (USD MILLION) 158 TABLE 137 NORTH AMERICA: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 138 EUROPE: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION) 159 TABLE 139 ASIA PACIFIC: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 140 LATIN AMERICA: SACRAL NERVE STIMULATION MARKET FOR FECAL INCONTINENCE, BY COUNTRY, 2023–2030 (USD MILLION) 160 TABLE 141 NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 161 TABLE 142 VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY REGION, 2023–2030 (USD MILLION) 161 TABLE 143 NORTH AMERICA: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 144 EUROPE: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023–2030 (USD MILLION) 162 TABLE 145 ASIA PACIFIC: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 146 LATIN AMERICA: VAGUS NERVE STIMULATION MARKET FOR EPILEPSY, BY COUNTRY, 2023–2030 (USD MILLION) 163 TABLE 147 OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 164 TABLE 148 NORTH AMERICA: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 149 EUROPE: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 150 ASIA PACIFIC: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 165 TABLE 151 LATIN AMERICA: OTHER VAGUS NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 166 TABLE 152 NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 166 TABLE 153 GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY REGION, 2023–2030 (USD MILLION) 167 TABLE 154 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023–2030 (USD MILLION) 167 TABLE 155 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 156 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023–2030 (USD MILLION) 168 TABLE 157 LATIN AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR GASTROPARESIS, BY COUNTRY, 2023–2030 (USD MILLION) 169 TABLE 158 GLOBAL NUMBERS OF ADULTS WITH OBESITY (BMI ≥30 KG/M2 ), BY REGION (BILLION) 169 TABLE 159 GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY REGION, 2023–2030 (USD MILLION) 170 TABLE 160 NORTH AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023–2030 (USD MILLION) 170 TABLE 161 EUROPE: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 162 ASIA PACIFIC: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023–2030 (USD MILLION) 171 TABLE 163 LATIN AMERICA: GASTRIC ELECTRICAL STIMULATION MARKET FOR OBESITY, BY COUNTRY, 2023–2030 (USD MILLION) 172 TABLE 164 NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 172 TABLE 165 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY REGION, 2023–2030 (USD MILLION) 173 TABLE 166 NORTH AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION) 173 TABLE 167 EUROPE: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 168 ASIA PACIFIC: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION) 174 TABLE 169 LATIN AMERICA: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION MARKET FOR TREATMENT-RESISTANT DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION) 175 TABLE 170 OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 176 TABLE 171 NORTH AMERICA: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 176 TABLE 172 EUROPE: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 173 ASIA PACIFIC: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 177 TABLE 174 LATIN AMERICA: OTHER TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 178 TABLE 175 NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 178 TABLE 176 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY REGION, 2023–2030 (USD MILLION) 179 TABLE 177 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION) 179 TABLE 178 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 179 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION) 180 TABLE 180 LATIN AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR DEPRESSION, BY COUNTRY, 2023–2030 (USD MILLION) 181 TABLE 181 TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY REGION, 2023–2030 (USD MILLION) 181 TABLE 182 NORTH AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 183 EUROPE: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 184 ASIA PACIFIC: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 185 LATIN AMERICA: TRANSCRANIAL MAGNETIC STIMULATION MARKET FOR MIGRAINE, BY COUNTRY, 2023–2030 (USD MILLION) 183 TABLE 186 NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY REGION, 2023–2030 (USD MILLION) 184 TABLE 187 NORTH AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 184 TABLE 188 EUROPE: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 189 ASIA PACIFIC: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 185 TABLE 190 LATIN AMERICA: NEUROMODULATION MARKET FOR RESPIRATORY ELECTRICAL STIMULATION, BY COUNTRY, 2023–2030 (USD MILLION) 186 TABLE 191 OTHER NEUROMODULATION APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION) 186 TABLE 192 NORTH AMERICA: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 193 EUROPE: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 187 TABLE 194 ASIA PACIFIC: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 195 LATIN AMERICA: OTHER NEUROMODULATION APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 188 TABLE 196 NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 190 TABLE 197 NUMBER OF HOSPITALS PER CAPITA, BY COUNTRY, 2024 191 TABLE 198 NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY REGION, 2023–2030 (USD MILLION) 191 TABLE 199 NORTH AMERICA: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 200 EUROPE: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 192 TABLE 201 ASIA PACIFIC: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 202 LATIN AMERICA: NEUROMODULATION MARKET FOR HOSPITALS & AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 193 TABLE 203 NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY REGION, 2023–2030 (USD MILLION) 194 TABLE 204 NORTH AMERICA: NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 194 TABLE 205 EUROPE: NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 206 ASIA PACIFIC: NEUROMODULATION FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 195 TABLE 207 LATIN AMERICA: NEUROMODULATION MARKET FOR CLINICS & PHYSIOTHERAPY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 196 TABLE 208 NEUROMODULATION MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION) 196 TABLE 209 NORTH AMERICA: NEUROMODULATION MARKET FOR OTHER END USERS, 2023–2030 (USD MILLION) 197 TABLE 210 EUROPE: NEUROMODULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 197 TABLE 211 ASIA PACIFIC: NEUROMODULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION) 198 TABLE 212 LATIN AMERICA: NEUROMODULATION MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION) 198 TABLE 213 NEUROMODULATION MARKET, BY REGION, 2023–2030 (USD MILLION) 200 TABLE 214 NORTH AMERICA: KEY MACROINDICATORS 200 TABLE 215 NORTH AMERICA: NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 202 TABLE 216 NORTH AMERICA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 202 TABLE 217 NORTH AMERICA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 203 TABLE 218 NORTH AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 203 TABLE 219 NORTH AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 204 TABLE 220 NORTH AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 204 TABLE 221 NORTH AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 204 TABLE 222 NORTH AMERICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 205 TABLE 223 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 205 TABLE 224 NORTH AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 205 TABLE 225 NORTH AMERICA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 206 TABLE 226 US: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 207 TABLE 227 US: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 207 TABLE 228 US: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 208 TABLE 229 US: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 208 TABLE 230 US: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 208 TABLE 231 US: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 209 TABLE 232 US: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 209 TABLE 233 US: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 209 TABLE 234 US: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 210 TABLE 235 US: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 210 TABLE 236 CANADA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 211 TABLE 237 CANADA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 211 TABLE 238 CANADA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 212 TABLE 239 CANADA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 212 TABLE 240 CANADA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 212 TABLE 241 CANADA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 213 TABLE 242 CANADA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 213 TABLE 243 CANADA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 213 TABLE 244 CANADA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 214 TABLE 245 CANADA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 214 TABLE 246 EUROPE: KEY MACROINDICATORS 215 TABLE 247 EUROPE: NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 216 TABLE 248 EUROPE: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 216 TABLE 249 EUROPE: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 217 TABLE 250 EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 217 TABLE 251 EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 218 TABLE 252 EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 218 TABLE 253 EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 218 TABLE 254 EUROPE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 219 TABLE 255 EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 219 TABLE 256 EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 219 TABLE 257 EUROPE: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 220 TABLE 258 GERMANY: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 220 TABLE 259 GERMANY: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 221 TABLE 260 GERMANY: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 221 TABLE 261 GERMANY: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 222 TABLE 262 GERMANY: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 222 TABLE 263 GERMANY: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 222 TABLE 264 GERMANY: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 223 TABLE 265 GERMANY: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 223 TABLE 266 GERMANY: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 223 TABLE 267 GERMANY: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 224 TABLE 268 FRANCE: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 224 TABLE 269 FRANCE: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 225 TABLE 270 FRANCE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 225 TABLE 271 FRANCE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 226 TABLE 272 FRANCE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 226 TABLE 273 FRANCE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 226 TABLE 274 FRANCE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 227 TABLE 275 FRANCE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 227 TABLE 276 FRANCE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 227 TABLE 277 FRANCE: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 228 TABLE 278 UK: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 228 TABLE 279 UK: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 229 TABLE 280 UK: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 229 TABLE 281 UK: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 230 TABLE 282 UK: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 230 TABLE 283 UK: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 230 TABLE 284 UK: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 231 TABLE 285 UK: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 231 TABLE 286 UK: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 231 TABLE 287 UK: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 232 TABLE 288 ITALY: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 232 TABLE 289 ITALY: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 233 TABLE 290 ITALY: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 233 TABLE 291 ITALY: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 234 TABLE 292 ITALY: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 234 TABLE 293 ITALY: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 234 TABLE 294 ITALY: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 235 TABLE 295 ITALY: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 235 TABLE 296 ITALY: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 235 TABLE 297 ITALY: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 236 TABLE 298 SPAIN: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 236 TABLE 299 SPAIN: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 237 TABLE 300 SPAIN: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 237 TABLE 301 SPAIN: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 238 TABLE 302 SPAIN: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 238 TABLE 303 SPAIN: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 238 TABLE 304 SPAIN: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 239 TABLE 305 SPAIN: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 239 TABLE 306 SPAIN: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 239 TABLE 307 SPAIN: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 240 TABLE 308 RUSSIA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 240 TABLE 309 RUSSIA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 241 TABLE 310 RUSSIA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 241 TABLE 311 RUSSIA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 242 TABLE 312 RUSSIA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 242 TABLE 313 RUSSIA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 242 TABLE 314 RUSSIA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 243 TABLE 315 RUSSIA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 243 TABLE 316 RUSSIA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 243 TABLE 317 RUSSIA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 244 TABLE 318 REST OF EUROPE: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 244 TABLE 319 REST OF EUROPE: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 245 TABLE 320 REST OF EUROPE: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 245 TABLE 321 REST OF EUROPE: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 246 TABLE 322 REST OF EUROPE: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 246 TABLE 323 REST OF EUROPE: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 246 TABLE 324 REST OF EUROPE: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 247 TABLE 325 REST OF EUROPE: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 247 TABLE 326 REST OF EUROPE: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 247 TABLE 327 REST OF EUROPE: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 248 TABLE 328 ASIA PACIFIC: KEY MACROINDICATORS 249 TABLE 329 ASIA PACIFIC: NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 250 TABLE 330 ASIA PACIFIC: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 250 TABLE 331 ASIA PACIFIC: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 251 TABLE 332 ASIA PACIFIC: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 251 TABLE 333 ASIA PACIFIC: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 252 TABLE 334 ASIA PACIFIC: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 252 TABLE 335 ASIA PACIFIC: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 252 TABLE 336 ASIA PACIFIC: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 253 TABLE 337 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 253 TABLE 338 ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 253 TABLE 339 ASIA PACIFIC: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 254 TABLE 340 CHINA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 254 TABLE 341 CHINA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 255 TABLE 342 CHINA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 255 TABLE 343 CHINA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 256 TABLE 344 CHINA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 256 TABLE 345 CHINA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 256 TABLE 346 CHINA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 257 TABLE 347 CHINA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 257 TABLE 348 CHINA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 257 TABLE 349 CHINA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 258 TABLE 350 JAPAN: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 258 TABLE 351 JAPAN: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 259 TABLE 352 JAPAN: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 259 TABLE 353 JAPAN: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 260 TABLE 354 JAPAN: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 260 TABLE 355 JAPAN: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 260 TABLE 356 JAPAN: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 261 TABLE 357 JAPAN: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 261 TABLE 358 JAPAN: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 261 TABLE 359 JAPAN: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 262 TABLE 360 INDIA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 262 TABLE 361 INDIA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 263 TABLE 362 INDIA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 263 TABLE 363 INDIA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 264 TABLE 364 INDIA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 264 TABLE 365 INDIA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 264 TABLE 366 INDIA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 265 TABLE 367 INDIA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 265 TABLE 368 INDIA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 265 TABLE 369 INDIA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 266 TABLE 370 AUSTRALIA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 266 TABLE 371 AUSTRALIA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 267 TABLE 372 AUSTRALIA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 267 TABLE 373 AUSTRALIA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 268 TABLE 374 AUSTRALIA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 268 TABLE 375 AUSTRALIA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 268 TABLE 376 AUSTRALIA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 269 TABLE 377 AUSTRALIA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 269 TABLE 378 AUSTRALIA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 269 TABLE 379 AUSTRALIA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 270 TABLE 380 REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 271 TABLE 381 REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 271 TABLE 382 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 272 TABLE 383 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 272 TABLE 384 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 272 TABLE 385 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 273 TABLE 386 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 273 TABLE 387 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 273 TABLE 388 REST OF ASIA PACIFIC: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 274 TABLE 389 REST OF ASIA PACIFIC: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 274 TABLE 390 LATIN AMERICA: KEY MACROINDICATORS 275 TABLE 391 LATIN AMERICA: NEUROMODULATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 275 TABLE 392 LATIN AMERICA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 275 TABLE 393 LATIN AMERICA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 276 TABLE 394 LATIN AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 276 TABLE 395 LATIN AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 277 TABLE 396 LATIN AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 277 TABLE 397 LATIN AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 277 TABLE 398 LATIN AMERICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 278 TABLE 399 LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 278 TABLE 400 LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 278 TABLE 401 LATIN AMERICA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 279 TABLE 402 BRAZIL: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 280 TABLE 403 BRAZIL: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 280 TABLE 404 BRAZIL: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 281 TABLE 405 BRAZIL: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 281 TABLE 406 BRAZIL: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 281 TABLE 407 BRAZIL: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 282 TABLE 408 BRAZIL: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 282 TABLE 409 BRAZIL: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 282 TABLE 410 BRAZIL: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 283 TABLE 411 BRAZIL: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 283 TABLE 412 MEXICO: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 284 TABLE 413 MEXICO: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 284 TABLE 414 MEXICO: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 285 TABLE 415 MEXICO: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 285 TABLE 416 MEXICO: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 285 TABLE 417 MEXICO: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 286 TABLE 418 MEXICO: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 286 TABLE 419 MEXICO: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 286 TABLE 420 MEXICO: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 287 TABLE 421 MEXICO: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 287 TABLE 422 REST OF LATIN AMERICA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 288 TABLE 423 REST OF LATIN AMERICA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 288 TABLE 424 REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 289 TABLE 425 REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 289 TABLE 426 REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 289 TABLE 427 REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 290 TABLE 428 REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 290 TABLE 429 REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 290 TABLE 430 REST OF LATIN AMERICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 291 TABLE 431 REST OF LATIN AMERICA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 291 TABLE 432 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 292 TABLE 433 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 292 TABLE 434 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY STIMULATION TYPE, 2023–2030 (USD MILLION) 293 TABLE 435 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 293 TABLE 436 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR DEEP BRAIN STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 294 TABLE 437 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR SACRAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 294 TABLE 438 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR VAGUS NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 294 TABLE 439 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR GASTRIC ELECTRICAL STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 295 TABLE 440 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 295 TABLE 441 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET FOR TRANSCRANIAL MAGNETIC STIMULATION, BY APPLICATION, 2023–2030 (USD MILLION) 295 TABLE 442 MIDDLE EAST & AFRICA: NEUROMODULATION MARKET, BY END USER, 2023–2030 (USD MILLION) 296 TABLE 443 MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN NEUROMODULATION MARKET, JANUARY 2022–JULY 2025 297 TABLE 444 NEUROMODULATION MARKET: DEGREE OF COMPETITION 300 TABLE 445 NEUROMODULATION MARKET: REGION FOOTPRINT 303 TABLE 446 NEUROMODULATION MARKET: TECHNOLOGY FOOTPRINT 304 TABLE 447 NEUROMODULATION MARKET: STIMULATION TYPE FOOTPRINT 304 TABLE 448 NEUROMODULATION MARKET: END-USER FOOTPRINT 305 TABLE 449 NEUROMODULATION MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 307 TABLE 450 NEUROMODULATION MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY TECHNOLOGY AND REGION 308 TABLE 451 NEUROMODULATION MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 312 TABLE 452 NEUROMODULATION MARKET: DEALS, JANUARY 2022–JULY 2025 313 TABLE 453 MEDTRONIC: COMPANY OVERVIEW 314 TABLE 454 MEDTRONIC: PRODUCTS OFFERED 316 TABLE 455 MEDTRONIC: PRODUCT APPROVALS, JANUARY 2022–JULY 2025 316 TABLE 456 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 318 TABLE 457 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 320 TABLE 458 BOSTON SCIENTIFIC CORPORATION: PRODUCT APPROVALS, JANUARY 2022–JULY 2025 320 TABLE 459 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2022–JULY 2025 321 TABLE 460 ABBOTT: COMPANY OVERVIEW 322 TABLE 461 ABBOTT: PRODUCTS OFFERED 323 TABLE 462 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–JULY 2025 324 TABLE 463 LIVANOVA PLC: COMPANY OVERVIEW 325 TABLE 464 LIVANOVA PLC: PRODUCTS OFFERED 326 TABLE 465 LIVANOVA PLC: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025 327 TABLE 466 NEVRO CORP.: COMPANY OVERVIEW 328 TABLE 467 NEVRO CORP.: PRODUCTS OFFERED 329 TABLE 468 NEVRO CORP.: PRODUCT APPROVALS, JANUARY 2022–JULY 2025 329 TABLE 469 NEVRO CORP.: DEALS, JANUARY 2022–JULY 2025 330 TABLE 470 NEUROPACE, INC.: COMPANY OVERVIEW 331 TABLE 471 NEUROPACE, INC.: PRODUCTS OFFERED 332 TABLE 472 BIOVENTUS: COMPANY OVERVIEW 333 TABLE 473 BIOVENTUS: PRODUCTS OFFERED 334 TABLE 474 BIOVENTUS: PRODUCT APPROVALS, JANUARY 2022–JULY 2025 335 TABLE 475 ELECTROCORE, INC.: COMPANY OVERVIEW 336 TABLE 476 ELECTROCORE, INC.: PRODUCTS OFFERED 337 TABLE 477 ELECTROCORE, INC.: PRODUCT LAUNCHES, JANUARY 2022–JULY 2025 338 TABLE 478 ELECTROCORE, INC.: DEALS, JANUARY 2022–JULY 2025 338 TABLE 479 HELIUS MEDICAL TECHNOLOGIES, INC.: COMPANY OVERVIEW 339 TABLE 480 HELIUS MEDICAL TECHNOLOGIES, INC.: PRODUCTS OFFERED 340 TABLE 481 HELIUS MEDICAL TECHNOLOGIES, INC.: DEALS, JANUARY 2022–JULY 2025 341 TABLE 482 NEURONETICS: COMPANY OVERVIEW 342 TABLE 483 NEURONETICS: PRODUCTS OFFERED 343 TABLE 484 NEURONETICS: PRODUCT APPROVALS, JANUARY 2022–JULY 2025 344 TABLE 485 NEURONETICS: DEALS, JANUARY 2022–JULY 2025 344 TABLE 486 NEUROSIGMA, INC.: COMPANY OVERVIEW 345 TABLE 487 SOTERIX MEDICAL INC.: COMPANY OVERVIEW 346 TABLE 488 SYNAPSE BIOMEDICAL INC.: COMPANY OVERVIEW 347 TABLE 489 ALEVA NEUROTHERAPEUTICS: COMPANY OVERVIEW 348 TABLE 490 THERANICA BIO-ELECTRONICS LTD.: COMPANY OVERVIEW 349 TABLE 491 GIMER MEDICAL: COMPANY OVERVIEW 350 TABLE 492 NALU MEDICAL, INC.: COMPANY OVERVIEW 351 TABLE 493 MICROTRANSPONDER INC.: COMPANY OVERVIEW 351 TABLE 494 MAGSTIM: COMPANY OVERVIEW 352 TABLE 495 AMBER THERAPEUTICS: COMPANY OVERVIEW 353 TABLE 496 TVNS TECHNOLOGIES GMBH: COMPANY OVERVIEW 354 TABLE 497 BIOWAVE: COMPANY OVERVIEW 355 TABLE 498 BIOTRONIK: COMPANY OVERVIEW 356 TABLE 499 SALUDA MEDICAL PTY LTD.: COMPANY OVERVIEW 357 TABLE 500 SPR: COMPANY OVERVIEW 358 FIGURE 1 NEUROMODULATION MARKET SEGMENTATION & REGIONAL SCOPE 38 FIGURE 2 NEUROMODULATION MARKET: YEARS CONSIDERED 40 FIGURE 3 NEUROMODULATION MARKET: RESEARCH DESIGN 43 FIGURE 4 NEUROMODULATION MARKET: KEY DATA FROM SECONDARY SOURCES 44 FIGURE 5 LIST OF PRIMARY SOURCES IN NEUROMODULATION MARKET 45 FIGURE 6 NEUROMODULATION MARKET: BREAKDOWN OF PRIMARY INTERVIEWS, BY COMPANY TYPE, DESIGNATION, AND REGION 47 FIGURE 7 KEY INSIGHTS FROM PRIMARY EXPERTS IN NEUROMODULATION MARKET 48 FIGURE 8 REVENUE ESTIMATION OF KEY PLAYERS IN NEUROMODULATION MARKET 49 FIGURE 9 CAGR PROJECTIONS INNEUROMODULATION MARKET 50 FIGURE 10 NEUROMODULATION MARKET: TOP-DOWN APPROACH 50 FIGURE 11 NEUROMODULATION MARKET: DATA TRIANGULATION 51 FIGURE 12 PARAMETRIC ASSUMPTIONS IN NEUROMODULATION MARKET 52 FIGURE 13 NEUROMODULATION MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION) 55 FIGURE 14 NEUROMODULATION MARKET, BY STIMULATION TYPE, 2025 VS. 2030 (USD MILLION) 56 FIGURE 15 NEUROMODULATION MARKET FOR SPINAL CORD STIMULATION, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 57 FIGURE 16 NEUROMODULATION MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 57 FIGURE 17 REGIONAL SNAPSHOT OF NEUROMODULATION MARKET 58 FIGURE 18 RISE IN GERIATRIC POPULATION AND HIGH DEMAND FOR ADVANCED NEUROMODULATION THERAPIES TO DRIVE MARKET 59 FIGURE 19 CHINA AND HOSPITALS & AMBULATORY SURGERY CENTERS COMMANDED SIGNIFICANT MARKET SHARES IN 2024 60 FIGURE 20 CHINA TO ACCOUNT FOR HIGHEST CAGR DURING STUDY PERIOD 61 FIGURE 21 ASIA PACIFIC TO EXHIBIT FASTEST GROWTH DURING FORECAST PERIOD 62 FIGURE 22 NEUROMODULATION MARKET DYNAMICS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 63 FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS IN NEURMODULATION MARKET 69 FIGURE 24 NEUROMODULATION MARKET: VALUE CHAIN ANALYSIS 72 FIGURE 25 NEUROMODULATION MARKET: SUPPLY CHAIN ANALYSIS 73 FIGURE 26 NEUROMODULATION MARKET: ECOSYSTEM ANALYSIS 75 FIGURE 27 FUNDING AND NUMBER OF DEALS IN NEUROMODULATION MARKET, 2021–2024 (USD MILLION) 76 FIGURE 28 NEUROMODULATION MARKET: TOP 10 PATENT APPLICANTS/OWNERS AND NUMBER OF PATENTS APPLIED/GRANTED, 2015–2024 78 FIGURE 29 NEUROMODULATION MARKET: PORTER’S FIVE FORCES ANALYSIS 89 FIGURE 30 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY END USER 91 FIGURE 31 KEY BUYING CRITERIA, BY END USER 92 FIGURE 32 IMPACT OF AI ON NEUROMODULATION MARKET 93 FIGURE 33 NORTH AMERICA: NEUROMODULATION MARKET SNAPSHOT 201 FIGURE 34 NUMBER OF PATIENTS WITH ALZHEIMER’S IN US, 2020–2060 (MILLION) 206 FIGURE 35 ASIA PACIFIC: NEUROMODULATION MARKET SNAPSHOT 249 FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN NEUROMODULATION MARKET, 2020–2024 (USD MILLION) 299 FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN NEUROMODULATION MARKET (2024) 300 FIGURE 38 NEUROMODULATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 302 FIGURE 39 NEUROMODULATION MARKET: COMPANY FOOTPRINT 303 FIGURE 40 NEUROMODULATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 306 FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND FIVE-YEAR STOCK BETA OF KEY VENDORS 310 FIGURE 42 EV/EBITDA OF KEY VENDORS 310 FIGURE 43 NEUROMODULATION MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 311 FIGURE 44 MEDTRONIC: COMPANY SNAPSHOT 315 FIGURE 45 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 319 FIGURE 46 ABBOTT: COMPANY SNAPSHOT 323 FIGURE 47 LIVANOVA PLC: COMPANY SNAPSHOT 326 FIGURE 48 NEVRO CORP.: COMPANY SNAPSHOT 329 FIGURE 49 NEUROPACE, INC.: COMPANY SNAPSHOT 331 FIGURE 50 BIOVENTUS: COMPANY SNAPSHOT 334 FIGURE 51 ELECTROCORE, INC.: COMPANY SNAPSHOT 337 FIGURE 52 HELIUS MEDICAL TECHNOLOGIES, INC.: COMPANY SNAPSHOT 340 FIGURE 53 NEURONETICS: COMPANY SNAPSHOT 343

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們